OcuTerra Therapeutics
0 followers
OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity
Org chart
Kerrie Brady
CEO, President & Board Member
Kerrie Brady
Collapse
David J. Tanzer
Chief Medical Officer
Susannah Sinozich
Senior Clinical Program Director
Alexis Meng
Director, Business Operations
